Results 31 to 40 of about 19,002 (159)

Ziv-aflibercept: a novel option for the treatment of polypoidal choroidal vasculopathy. [PDF]

BMJ Case Rep, 2015
Polypoidal choroidal vasculopathy (PCV) is an exudative maculopathy usually treated using photodynamic therapy (PDT) and antivascular endothelial growth factor agents. However, these cases may sometimes be refractory to both PDT and ranibizumab or bevacizumab, and may have persistent intra-retinal fluid. Recently, studies have reported that aflibercept
Videkar C, Kapoor A, Chhablani J, Narayanan R.   +3 more
europepmc   +4 more sources

An In Vitro Evaluation of a New Approach in AMD: Effects of the Combination of Resveratrol and Anti-VEGFs on ARPE-19 Cells [PDF]

Biomolecules
Anti-vascular endothelial growth factor agents (anti-VEGFs) are the cornerstone of treatment for neovascular age-related macular degeneration (AMD). Resveratrol is a natural polyphenol with well-established antioxidant and anti-apoptotic properties. This
Onur Konukcu, Mehmet Argun, Semra Acer, Ömer Çelik, Özlem Tök, Levent Tök, Mustafa Nazıroğlu   +6 more
doaj   +2 more sources

Role of peripheral pan-retinal photocoagulation in diabetic macular edema treated with intravitreal ziv-aflibercept [PDF]

Clinical Ophthalmology, 2019
Ahmad M Mansour,1,2 Khalil El Jawhari,3 J Fernando Arevalo4 1Department of Ophthalmology, American University of Beirut, Beirut, Lebanon; 2Department of Ophthalmology, Rafik Hariri University Hospital, Beirut, Lebanon; 3Medical School, Medical ...
Mansour AM, El Jawhari K, Arevalo JF
doaj   +2 more sources

Safety of intravitreal ziv-aflibercept in choroido-retinal vascular diseases: A randomised double-blind intervention study. [PDF]

PLoS ONE, 2019
AIM:To evaluate the safety of 1.25mg and 2mg intravitreal ziv-aflibercept (IVZ) in Ghanaian eyes with choroido-retinal vascular diseases. DESIGN:Prospective, randomised, double blind, interventional study.
Imoro Zeba Braimah, Ernest Kenu, Kwesi N Amissah-Arthur, Stephen Akafo, Kwaku Oppong Kwarteng, Winfried M Amoaku   +5 more
doaj   +2 more sources

Fusion proteins for treatment of retinal diseases: aflibercept, ziv-aflibercept, and conbercept. [PDF]

Int J Retina Vitreous, 2016
In the last few years, monoclonal antibodies have revolutionized the treatment of retinal neovascular diseases. More recently, a different class of drugs, fusion proteins, has provided an alternative treatment strategy with pharmacological differences.
de Oliveira Dias JR, de Andrade GC, Novais EA, Farah ME, Rodrigues EB.   +4 more
europepmc   +4 more sources

Ziv-aflibercept plus pembrolizumab in patients with advanced melanoma resistant to anti-PD-1 treatment [PDF]

Cancer Immunology, Immunotherapy
F Stephen Hódi
exaly   +2 more sources

Erratum to "Osteonecrosis of the jaw associated with ziv-aflibercept". [PDF]

J Gastrointest Oncol, 2017
europepmc   +3 more sources

Retinal pigment epithelium rip following single intravitreal ziv-aflibercept injection [PDF]

Indian Journal of Ophthalmology, 2018
Sumit Randhir Singh, Jay Chhablani
doaj   +2 more sources

Complications of Ziv-Aflibercept in Choroidal and Retinal Vascular Diseases

Open Journal of Ophthalmology, 2023
Hussain Ahmad Khaqan, Usman Imtiaz, Laraib Hassan, Sabah Eric, Hasnain Muhammad Bukhsh, Hafiz Mubashir Farooqui, Ahmad Fauzan, Muhammad Usman Zia   +7 more
exaly   +2 more sources

FOLFOX plus ziv‐aflibercept or placebo in first‐line metastatic esophagogastric adenocarcinoma: A double‐blind, randomized, multicenter phase 2 trial [PDF]

Cancer, 2019
James Cleary
exaly   +2 more sources